Ingenious e-skin invented by scientists from the University of Glasgow improves the performance of prosthetic limbs through sensitive sensors.
Read more
History has shown us that only violence or huge disasters tend to reduce inequality. Which is frightening on it’s own.
The Great Leveller: Violence and the History of Inequality from the Stone Age to the Twenty-First Century By Walter Scheidel. Princeton University Press; 504 pages; $35 and £27.95.
AS A supplier of momentary relief, the Great Depression seems an unlikely candidate. But when it turns up on page 363 of Walter Scheidel’s “The Great Leveler” it feels oddly welcome. For once—and it is only once, for no other recession in American history boasts the same achievement—real wages rise and the incomes of the most affluent fall to a degree that has a “powerful impact on economic inequality”. Yes, it brought widespread suffering and dreadful misery. But it did not bring death to millions, and in that it stands out.
Read more
In case you missed it, Elon Musk is rather concerned about the fate of humanity, given the extreme advancements being made in artificial intelligence (AI). Ultimately, he fears that our AI will, one day, overtake us. When this happens, he claims that humans will likely become second class citizens (or slaves, or something even worse).
Now, reports have surfaced which assert that he is backing a brain-computer interface venture that was founded to allow humans to keep up with the advancements made in machines. The interface is intended to work by augmenting that which makes us human: our brains.
The find comes from The Wall Street Journal. According to them, the company – which is called Neuralink – is still in the earliest stages of development. To that end, it has no public presence at all.
Read more
Empresário Elon Musk tem uma nova empresa — sim, outra — focada no desenvolvimento das capacidades do cérebro através do aumento tecnológico. O Neuralink, vai trabalhar em tecnologia de interface computador-cérebro como meio de ajudar os seres humanos a acompanhar o desenvolvimento acelerado de inteligência artificial.
Read more
This is big: Is the Singularity a step closer?
Tesla Inc founder and Chief Executive Elon Musk has launched a company called Neuralink Corp through which computers could merge with human brains, the Wall Street Journal reported, citing people familiar with the matter.
Neuralink is pursuing what Musk calls the “neural lace” technology, implanting tiny brain electrodes that may one day upload and download thoughts, the Journal reported. (on.wsj.com/2naUATf)
Musk has not made an official announcement, but Neuralink was registered in California as a “medical research” company last July, and he plans on funding the company mostly by himself, a person briefed on the plans told the Journal.
Read more
“In today’s world, we are increasingly hearing calls for global competencies; that is, we are seeing demand for skills such as critical thinking and creativity across both manual and professional occupations.”
An exclusive interview with Ichor, the biotech company pioneering a SENS based repair therapy that could help cure age related blindness.
Check out our exclusive interview with Ichor the company taking the first SENS based therapy to the clinic. Should clinical trials be a success this will mark the arrival of a technology that addresses one of the aging processes.
Read more
Driverless vehicles operated by Uber Technologies Inc [UBER.UL] were back on the road in San Francisco on Monday after one of its self-driving cars crashed in Arizona, the ride-hailing company said.
Uber’s autonomous vehicles in Arizona and Pittsburgh, Pennsylvania, remained grounded but were expected to be operating again soon, according to a spokeswoman for the company, who refused to be identified.
“We are resuming our development operations in San Francisco this morning,” she said in an email.
Read more
Are 3D printed pills the future? We visited a London laboratory to find out.
Established by academics from University College London (UCL) in 2014, FabRx is a company seeking commercialize 3D printed medicines and devices. On the principle that everyone is different, the vision of 3D printed pills it to be able to provide more personal and specific care to patients in need.
Dr. Alvaro Goyanes is one of the four founding partners of FabRx and the company’s director of development. Dr. Goyanes invited 3D Printing Industry into the lab at UCL’s School of Pharmacy to find out more about the ongoing FabRx research.
Read more